According to seattlebusinessmag.com, Clay Siegall is the co-founder, chairman, and CEO of Seattle Genetics. The company headquarters is in Bothell. The antibodies of human lie at the core of what the company has been studying, operating and eventually packaging into medicines since its establishment in the year 1998. The power of the Seattle Genetics’ antibodies lives in their capability of connecting to something else, which is therapy. The antibody produces a toxic payload inside a cancer cell to eliminate it from the interior.
It is a strategy that can propel Seattle Genetics to join the big leagues. Many people are hoping it will become a company for pharmaceutical the biotech community of Seattle has long attempted to anchor using the cycles of up and down that have been plaguing the sector. Possessing a market value of almost $10 billion and also a list of 900 workers, Seattle Genetics is already ranking as the biggest biotech in WA. With great aspirations of becoming one of the few companies that move up from biotech to big pharma.
It’s investing heavily in marketing and research and expecting to add 200 employees. Adcetris, the flagship drug of the company, treats Hodgkin lymphoma (HL), a lymph system cancer that could spread to other organs. It’s sales start if the extensive tests on going prove positive.
Siegall stated that they are an emerging global, multi-product, company for oncology. His goals are obvious in his wish of moving beyond the more typical focus of biotech on the development of drug toward controlling all the international marketing complexities of its newer drug. After studying the global market through the partnership of Takeda with Seattle Genetics, Siegall opened a Switzerland-based office to let Seattle Genetics do its international marketing.
Siegall is the co-founder of Seattle Genetics. He launched the company in the year 1998. Under his leadership, the company built multiple pipelines of antibody-based therapies for cancer. He guided Seattle Genetics, activities for raising capital, securing over $675 million through private and public financings, including the initial public offering of the company in the year 2001.
Siegall serves a private biotechnology company, Alder BioPharmaceuticals on the B of D (Board of Directors). He’s the author of over 70 publications holding 15 patents. He studied at George Washington University, where he earned his Ph.D. in Genetics. He also went to study at UM (University of Maryland) and received a BSc in Zoology.